Navigation Links
Volunteers sought for avian flu vaccine study

Vanderbilt University Medical Center is enrolling volunteers in a study to test a new vaccine that targets avian flu, the first such vaccine against the virus. The Vanderbilt trial, led by Kathryn Edwards, M.D., will test the new vaccine in nearly 100 individuals 65 years of age and over. It is the second phase of anational study led by the National Institute of Allergy and Infectious Diseases.

The first phase of the avian flu vaccine trial, conducted at various other medical centers around the country, tested the vaccine in normal, healthy adults and determined it was safe to test in other populations.

The development of a widespread epidemic of avian influenza, or "birdflu," is of growing concern throughout the world.

Human cases, with a high fatality rate, have been reported in Vietnam, Thailand and Cambodia. Public health experts fear that avian flu could lead to a worldwide pandemic if the virus becomes easily transmittable,leading to a public health crisis.

Currently, most people are highly vulnerable to infection from avianinfluenza, as the current influenza vaccines do not protect against thisnew strain of the virus, making the development of new vaccines againstavian flu a major priority.

"We believe in some cases in Asia that the avian flu has been passed from human to human, and we're concerned that the virus will evolve to spread easily among the human population and become a global pandemic,"said Edwards, professor of Pediatric Infectious Diseases and vice chairof clinical research in the Department of Pediatrics.

"Developing an effective vaccine is our best defense. The elderly, in particular, could be at high risk for complications and death from infection, so it is very important to test the new vaccine in older adults."

Avian flu first emerged in Hong Kong in 1997 and has spread among poultry populations in some Asian countries. Humans have contracted the virus from sick animals, and evidenc e has pointed to a small number ofcases in which human-to-human transmission is believed to have occurred. Identified as H5N1, the strain of the influenza virus has shown a high mortality rate - approximately 72 percent - with many fatalities among previously healthy young people.

The vaccine researchers are testing was made by Sanofi Pasteur from an inactivated H5N1 avian flu virus isolated last year.

"It's similar to the concept of the regular flu vaccine that people get every year, but it's targeted to this novel type of flu," Edwards said.

Because the study is beginning at the start of this year's influenza season, all participants will be given this year's licensed influenza vaccine if desired. Participants will then be given three doses of either the bird flu or placebo vaccine over the next six months and will be required to provide blood samples to test if protection against the virus was produced.

People 65 years or older who are interested in hearing more about the avian flu vaccine study, may call the Avian Influenza Hotline at 615-322-8740.


'"/>

Source:Vanderbilt University Medical Center


Related biology news :

1. Long-sought flower-inducing molecule found
2. Better beetle sought for salt cedar control
3. Improved predictions of warming-induced extinctions sought
4. Scripps research team sheds light on long-sought cold sensation gene
5. Bird samples from Mongolia confirmed as H5N1 avian flu
6. WCS says avian flu prevention should focus on farms, markets
7. Less virulent strains of avian influenza can infect humans
8. Drug resistant avian influenza viruses more common in Southeast Asia than North America
9. H5N1 avian flu virus vaccine induces immune responses in healthy adults
10. Vaccine provides 100 percent protection against avian flu virus in animal study
11. Medical experts: US unlikely to have enough vaccines to stop avian flu
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: